I just think that if you are going to release results why not say “on average patients that received rexlemestrocel had an improved ejection fraction from 28% to 45% rather than saying “12 months least squared was 5.0” it seems pretty ambiguous and neither you or I understand what that means
Ann: Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE, page-140
-
- There are more pages in this discussion • 160 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.5¢ |
Change
0.035(3.72%) |
Mkt cap ! $1.110B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 98.0¢ | 92.0¢ | $2.611M | 2.725M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 110350 | 97.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.5¢ | 75601 | 12 |
View Market Depth
| Last trade - 14.20pm 03/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |